 HOUSTON, July 1, 2021 PRNewswire -- CNS Pharmaceuticals, Inc. NASDAQ: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Recent Highlights Secured an additional 4.7 million in gross proceeds from ATM at average price of 2.32; extending the Companys cash runway to Q2 2022; Granted Fast Track Designation from the U.S. Food and Drug Administration FDA for lead investigational drug candidate, Berubicin, for the treatment of patients with recurrent GBM; and Commenced enrollment in potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. 